Briefing
SWOG S1803 DRAMMATIC: daratumumab-lenalidomide vs lenalidomide maintenance with MRD-adapted duration in newly diagnosed myeloma after transplant
Ongoing randomized MRD-adapted maintenance trial. No primary efficacy results paper was identified as of this review. Included as a level-1-design trial (MRD-integral randomization) without outcome data.
- Design: trial
- Assay: MRD-adapted maintenance duration